![What Is a Markup Language? [+ 7 Examples]](https://static.semrush.com/blog/uploads/media/82/c8/82c85ebca40c95d539cf4b766c9b98f8/markup-language-sm.png)
![[Weekly funding roundup June 21-27] A sharp rise in VC inflow](https://images.yourstory.com/cs/2/220356402d6d11e9aa979329348d4c3e/Weekly-funding-1741961216560.jpg)
2 Beaten-Down Stocks to Avoid
Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT), two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatility. Both drugmakers have seen their shares plummet over the trailing-12-month period. However, while investors are supposed to buy low, even at current levels, Editas Medicine and Sarepta aren't attractive stocks to buy.Let's consider why investors should stay a safe distance away from these two biotech companies.Image source: Getty Images.Continue reading
Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT), two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatility. Both drugmakers have seen their shares plummet over the trailing-12-month period. However, while investors are supposed to buy low, even at current levels, Editas Medicine and Sarepta aren't attractive stocks to buy.
Let's consider why investors should stay a safe distance away from these two biotech companies.
Image source: Getty Images.
